Alivus Life Sciences: A Stellar Q3 FY26 Performance Driven by Strategic Execution

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has reported an exceptional financial performance for the third quarter of fiscal year 2026, ending December 31, 2025. The company, a leading developer and manufacturer of high-value Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, announced its highest ever quarterly revenues and record-high EBITDA margins. This robust performance underscores Alivus's strategic focus on diversified growth, operational efficiency, and a strong product pipeline, positioning it favorably within the dynamic global pharmaceutical industry.

For Q3 FY26, Alivus registered a revenue from operations of Rs. 672.9 crore, marking a significant growth of 14.4% quarter-on-quarter (QoQ) and 4.8% year-on-year (YoY). This impressive top-line growth was complemented by an outstanding improvement in profitability, with EBITDA reaching Rs. 245.2 crore, a substantial increase of 26.5% QoQ and 22.1% YoY. The EBITDA margin soared to a record 36.4%, up 340 basis points QoQ and 510 basis points YoY, reflecting the company's enhanced operational efficiency and favorable product mix. Profit After Tax (PAT) for the quarter stood at Rs. 150.3 crore, growing 15.5% QoQ and 9.7% YoY, with PAT margins at 22.3%.

Segmental Strength and Strategic Diversification

The strong performance was broad-based, with significant contributions from both the Generic API and CDMO segments. The CDMO business, in particular, witnessed a remarkable recovery, growing 100% QoQ and 85.3% YoY. This turnaround was largely driven by new project contributions and sustained traction in existing CDMO projects, aligning with management's expectations for a stronger second half of the fiscal year. The Non-GPL (Non-Glenmark Pharmaceuticals Ltd.) business also demonstrated robust growth, expanding by 16.1% YoY during 9M FY26 across key markets including Europe, Japan, LATAM, ROW, and India. This diversification across geographies and business models highlights Alivus's resilience and ability to capture growth opportunities globally.

The company's revenue mix further illustrates its strategic positioning. Generic API contributed 92% of the total revenue, while CDMO accounted for 8%. In terms of therapeutic areas, chronic therapies continued to be a major growth driver, contributing 66% of the revenue, with acute therapies making up 34%. Geographically, regulated markets remained dominant, contributing 83% of the revenue, while emerging markets accounted for 17%. The GPL business, which contributed 30% of the total revenue, also saw a recovery, growing 40.4% QoQ and 13.8% YoY.

Operational Excellence and Future Capacity

Alivus's commitment to operational excellence and strategic capacity expansion is a cornerstone of its growth strategy. The company's gross margins improved to 58.9% in Q3 FY26, driven by new product launches, a favorable product mix, and enhanced operational efficiencies. Management emphasized that these efficiencies, including better yields and reduced raw material costs, are sustainable and contribute significantly to margin expansion.

On the capacity front, Alivus is actively pursuing both greenfield and brownfield expansions. The Solapur greenfield project, with Phase 1 and 1.1 construction for 465 KL capacity, is progressing, though with a slight delay, now expected to commence operations by July FY26. This plant will initially cater to ROW markets, with regulated products anticipated by late FY28. Brownfield expansions at Ankleshwar (~100 KL) and Dahej (~160 KL) are on track to be operational by Q2 FY27, providing crucial capacity for regulated markets. The company's R&D capabilities are also being bolstered with the acquisition of land in Taloja (Navi Mumbai) for a state-of-the-art R&D centre, focusing on complex chemistry, oncology research, flow chemistry, particle engineering, and green chemistry.

Financial Prudence and Outlook

Alivus maintains a strong financial position, operating as a net debt-free company. During 9M FY26, the company generated a robust free cash flow of Rs. 220.7 crore, leading to cash and cash equivalents (including short-term investments) of Rs. 733.0 crore as of December 31, 2025. This strong liquidity provides flexibility for future growth initiatives. The CAPEX guidance for FY26 has been revised to Rs. 450 crore, with Rs. 150 crore deferred to FY27, reflecting a calibrated approach to capacity expansion.

Looking ahead, management is confident in sustaining high single-digit revenue growth for FY26, driven by the continued momentum in the non-GPL business and the ramp-up of CDMO projects. They expect to maintain healthy EBITDA margins in the 30-32% range, higher than previous guidance. The company's robust pipeline, with 595 DMF and CEP filings globally and 27 HP API products in active development, further supports this positive outlook. Alivus Life Sciences is strategically positioned for sustained growth, leveraging its diversified portfolio, operational efficiencies, and continuous innovation to evolve and expand its market presence.